Males with lupus nephritis had higher all-cause mortality and proportion of infection-related death compared to females.

8 EULAR also advises clinicians to consider ... adds Gross. “After a lupus nephritis diagnosis, patients leave the office with their head spinning, trying to make sense of their disease and ...

Both guidelines mention the importance of HCQ and ACR suggests prescribing this drug to all lupus patients with nephritis. Therefore, EULAR has developed recommendations [85] for conducting ...

REPEAT kidney biopsies may play an essential role in managing lupus nephritis, particularly for patients whose disease ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Panelists discuss the challenges patients face in accessing lupus nephritis treatment and the resources available to support ...

Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis.

Roche announced positive topline results from the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated ...